Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome
Open Access
- 17 May 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 27 (12), 1472-1477
- https://doi.org/10.1093/eurheartj/ehl017
Abstract
Aims Advanced therapies (prostacyclin analogues, endothelin receptor antagonists) are successfully used in the treatment of idiopathic pulmonary arterial hypertension. In addition, patients with the Eisenmenger syndrome (ES) seem to benefit from these news drugs regarding symptoms, but there is still no evidence for changes in outcome. Methods and results The clinical course of 43 patients (M/F 13/30, age 34.0±12.7 years), registered with unstable ES in our database, was retrospectively analysed. These patients were divided into two groups: those treated with and those treated without advanced therapy. The primary endpoint was defined as death from any cause. Death or inscription on the active waiting list of heart–lung transplantation was considered as secondary endpoint. Kaplan–Meier survival and log rank testing were performed to determine differences in outcome between the two groups. The total cohort was followed for a median period of 4.9 (range 0.2–14.9) years. Mean survival time for patients treated with (n=26) and without (n=17) advanced therapy therapies were 8.5±1.5 and 8.5±0.9 years, respectively (log rank testing, P=0.31). However, the mean time to death or inscription on the active waiting list was significantly longer for patients treated with advanced therapy when compared with those without (7.8±1.0 vs. 3.4±0.9 years, P=0.006). Conclusion For the given follow-up period, no improvement in survival time could be documented in adult patients with unstable ES treated with advanced therapy. However, we might suggest with these data that the need for heart–lung transplantation can be substantially delayed with new drugs.This publication has 20 references indexed in Scilit:
- Survival with first-line bosentan in patients with primary pulmonary hypertensionEuropean Respiratory Journal, 2005
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survivalJournal of the American College of Cardiology, 2002
- Pulmonary arterial hypertension in congenital heart diseaseCardiology Clinics, 2002
- Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trialJournal of the American College of Cardiology, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2002
- Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2002
- The registry of the international society for heart and lung transplantation: sixteenth official report—1999The Journal of Heart and Lung Transplantation, 1999
- The Eisenmenger Syndrome in AdultsAnnals of Internal Medicine, 1998
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionThe New England Journal of Medicine, 1996